

Publikationsliste Prof. Dr. Erwin Blessing

1. Teichgräber U, Lehmann T, Ingwersen M, Aschenbach R, Zeller T, Brechtel K, **Blessing E**, Lichtenberg M, von Flotow P, Heilmeier B, Sixt S, Brucks S, Erbel C, Beschorner U, Werk M, Riambau V, Wienke A, Klumb C, Thieme M, Scheinert D. Long-Term Effectiveness and Safety of Femoropopliteal Drug-Coated Balloon Angioplasty: 5-Year Results of the Randomized Controlled EffPac Trial. *Cardiovasc Intervent Radiol*. 2022;doi:10.1007/s00270-022-03265-1.
2. Stoll F, Usul R, **Blessing E**, Frey N, Katus HA, Erbel C, Heilmeier B, Müller OJ. Drug-coated balloons in below-the-knee arteries. *Vasa*. 2022;51:256-262.
3. Zeller T, Giannopoulos S, Brodmann M, Werner M, Andrassy M, Schmidt A, **Blessing E**, Tepe G, Armstrong EJ. Orbital Atherectomy Prior to Drug-Coated Balloon Angioplasty in Calcified Infrapopliteal Lesions: A Randomized, Multicenter Pilot Study. *J Endovasc Ther*. 2022;doi:10.1177/15266028211070968.
4. Korosoglou G, **Blessing E**. Swirling flow vascular stent for the treatment of femoropopliteal lesions. *Vasa*. 2022;51:2-4.
5. Thieme M, Arjumand J, Spanagel M, Tepe G, **Blessing E**, Kroeg B, Reichert V, Betge S, Wickenhöfer R, Teßarek J, Ingwersen M, Krankenberg H. Stents With Torsial Strength for Superficial Femoral Artery Disease: The Prospective Q3-Registry. *J Endovasc Ther*. 2022; doi: 10.1177/15266028211067726.
6. Korosoglou G, Schmidt A, Stavroulakis K, Pollert D, Giusca S, Lichtenberg M, Scheinert D, Torsello G, Andrassy M, **Blessing E**. Retrograde Access for the Recanalization of Lower-Limb Occlusive Lesions: A German Experience Report in 1,516 Consecutive Patients. *JACC Cardiovasc Interv*. 2022; 15:348-351.
7. Patrone L, Dharmarajah B, Korosoglou G, Theivacumar S, Antaredja M, Oberacker R, Tilemann L, **Blessing E**. Retrograde use of the Outback re-entry catheter in complex infrainguinal arterial recanalizations. *J Vasc Surg*. 2022; 75:177-185.
8. Korosoglou G, Giusca S, Antaredja M, Schmidt A, **Blessing E**. Distal retrieval of dislodged and migrated guidewires after retrograde puncture of the deep femoral and dorsal pedal artery. A case series. *Clin Case Rep*. 2021;9:2077-2082.
9. Zylla MM, Merle U, Vey JA, Korosoglou G, Hofmann E, Müller M, Herth F, Schmidt W, **Blessing E**, Göggelmann C, Weidner N, Fiedler MO, Weigand MA, Kälble F, Morath C, Leiner J, Kieser M, Katus HA and Thomas D. Predictors and Prognostic Implications of Cardiac Arrhythmias in Patients Hospitalized for COVID-19. *J Clin Med*. 2021;10.
10. **Blessing E**, Antaredja M, Tilemann L and Oberacker R. Implantation of vascular mimetic implants in challenging chronic total occlusions - Supera(TM) Extreme. *Vasa*. 2020:1-5.
11. Brodmann M, Wissgott C, Brechtel K, Nikol S, Zeller T, Lichtenberg M, **Blessing E** and Gray W. Optimized drug-coated balloon angioplasty of the superficial femoral and proximal popliteal arteries using the Tack Endovascular System: TOBA III 12-month results. *J Vasc Surg*. 2020;72:1636-1647.e1.
12. Teichgräber U, Lehmann T, Aschenbach R, Scheinert D, Zeller T, Brechtel K, **Blessing E**, Lichtenberg M, von Flotow P, Heilmeier B, Sixt S, Brucks S, Erbel C, Beschorner U, Werk M, Riambau V, Wienke A, Klumb CT and Thieme M. Drug-coated Balloon Angioplasty of Femoropopliteal Lesions Maintained Superior Efficacy over Conventional Balloon: 2-year Results of the Randomized EffPac Trial. *Radiology*. 2020;295:478-487.
13. Kronlage M, Werner C, Dufner M, **Blessing E**, Müller OJ, Heilmeier B, Katus HA and Erbel C. Long-term outcome upon treatment of calcified lesions of the lower limb using scoring angioplasty balloon (AngioSculpt™). *Clin Res Cardiol*. 2020;109:1177-1185.

14. Steiner S, Schmidt A, Zeller T, Tepe G, Thieme M, Maiwald L, Schröder H, Euringer W, Ulrich M, Brechtel K, Brucks S, **Blessing E**, Schuster J, Langhoff R, Schellong S, Weiss N and Scheinert D. COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions. *Eur Heart J*. 2020;41:2541-2552.
15. Teichgräber U, Lehmann T, Aschenbach R, Scheinert D, Zeller T, Brechtel K, **Blessing E**, Lichtenberg M, Sixt S, Brucks S, Beschorner U, Klumb CT and Thieme M. Efficacy and safety of a novel paclitaxel-nano-coated balloon for femoropopliteal angioplasty: one-year results of the EffPac trial. *EuroIntervention*. 2020;15:e1633-e1640.
16. Schreve MA, Lichtenberg M, Ünlü Ç, Branzan D, Schmidt A, van den Heuvel DAF, **Blessing E**, Brodmann M, Cabane V, Lin WTQ and Kum S. PROMISE international; a clinical post marketing trial investigating the percutaneous deep vein arterialization (LimFlow) in the treatment of no-option chronic limb ischemia patient. *CVIR Endovasc*. 2019;2:26.
17. Kronlage M, **Blessing E**, Müller OJ, Heilmeyer B, Katus HA and Erbel C. Anticoagulation in addition to dual antiplatelet therapy has no impact on long-term follow-up after endovascular treatment of (sub)acute lower limb ischemia. *Vasa*. 2019;48:321-329.
18. **Blessing E**, Lugenbiel I and Holden A. The evidence to support the use of focal force balloon technology to improve outcomes in the treatment of lower extremity arterial occlusive disease. *J Cardiovasc Surg (Torino)*. 2019;60:14-20.
19. Chernin G, Szwarcfiter I, Scheinert D, **Blessing E**, Diehm N, Dens J, Walton A, Verheye S, Shetty S and Jonas M. First-in-Man Experience with a Novel Catheter-Based Renal Denervation System of Ultrasonic Ablation in Patients with Resistant Hypertension. *J Vasc Interv Radiol*. 2018;29:1158-1166.
20. Lugenbiel I, Grebner M, Zhou Q, Strothmeyer A, Vogel B, Cebola R, Müller O, Brado B, Mittnacht M, Kohler B, Katus H and **Blessing E**. Treatment of femoropopliteal lesions with the AngioSculpt scoring balloon - results from the Heidelberg PANTHER registry. *Vasa*. 2018;47:49-55.
21. Schroë H, Holden AH, Goueffic Y, Jansen SJ, Peeters P, Keirse K, Ito W, Vermassen F, Micari A, **Blessing E**, Jaff MR and Zeller T. Stellarex drug-coated balloon for treatment of femoropopliteal arterial disease-The ILLUMENATE Global Study: 12-Month results from a prospective, multicenter, single-arm study. *Catheter Cardiovasc Interv*. 2018;91:497-504.
22. Kronlage M, Wassmann M, Vogel B, Müller OJ, **Blessing E**, Katus H and Erbel C. Short vs prolonged dual antiplatelet treatment upon endovascular stenting of peripheral arteries. *Drug Des Devel Ther*. 2017;11:2937-2945.
23. Zeller T, Langhoff R, Rocha-Singh KJ, Jaff MR, **Blessing E**, Amann-Vesti B, Krzanowski M, Peeters P, Scheinert D, Torsello G, Sixt S and Tepe G. Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study. *Circ Cardiovasc Interv*. 2017;10:e004848.
24. Krankenberg H, Zeller T, Ingwersen M, Schmalstieg J, Gissler HM, Nikol S, Baumgartner I, Diehm N, Nickling E, Müller-Hülsbeck S, Schmiedel R, Torsello G, Hochholzer W, Stelzner C, Brechtel K, Ito W, Kickuth R, **Blessing E**, Thieme M, Nakonieczny J, Nolte T, Gareis R, Boden H and Sixt S. Self-Expanding Versus Balloon-Expandable Stents for Iliac Artery Occlusive Disease: The Randomized ICE Trial. *JACC Cardiovasc Interv*. 2017;10:1694-1704.
25. Zeller T, Krankenberg H, Erglis A, **Blessing E**, Fuss T, Scheinert D, Weser R, Doerr BB, Yollo WD and Radermacher J. A randomized, multi-center, prospective study comparing best medical treatment versus best medical treatment plus renal artery stenting in patients with hemodynamically relevant atherosclerotic renal artery stenosis (RADAR) - one-year results of a pre-maturely terminated study. *Trials*. 2017;18:380.

26. Heger T, Strauß S, **Blessing E**, Andrassy M, Erbel C, Müller OJ, Chorianopoulos E, Pleger S, Leuschner F, Korosoglou G, Bekeredjian R, Katus HA and Vogel B. Short and long-term results after endovascular management of vascular complications during transfemoral aortic valve implantation. *Acta Cardiol.* 2017;72:474-482.
27. Kronlage M, Printz I, Vogel B, **Blessing E**, Müller OJ, Katus HA and Erbel C. A comparative study on endovascular treatment of (sub)acute critical limb ischemia: mechanical thrombectomy vs thrombolysis. *Drug Des Devel Ther.* 2017;11:1233-1241.
28. Teichgräber U, Aschenbach R, Scheinert D, Zeller T, Brechtel K, Thieme M, **Blessing E**, Treitl M, Lichtenberg M, von Flotow P, Vogel B, Werk M, Rimbau V, Wienke A, Lehmann T and Sixt S. The effectiveness of the paclitaxel-coated Luminor® balloon catheter versus an uncoated balloon catheter in superficial femoral and popliteal arteries in preventing vessel restenosis or reocclusion: study protocol for a randomized controlled trial. *Trials.* 2016;17:528.
29. Ewen S, Ukena C, Lüscher TF, Bergmann M, Blankestijn PJ, **Blessing E**, Cremers B, Dörr O, Hering D, Kaiser L, Nef H, Noory E, Schlaich M, Sharif F, Sudano I, Vogel B, Voskuil M, Zeller T, Tzafiri AR, Edelman ER, Lauder L, Scheller B, Böhm M and Mahfoud F. Anatomical and procedural determinants of catheter-based renal denervation. *Cardiovasc Revasc Med.* 2016;17:474-479.
30. Preusch MR, Rusnak J, Staudacher K, Mogler C, Uhlmann L, Sievers P, Bea F, Katus HA, **Blessing E** and Staudacher I. Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis. *Drug Des Devel Ther.* 2016;10:2691-9.
31. Krankenberg H, Tübler T, Ingwersen M, Schlüter M, Scheinert D, **Blessing E**, Sixt S, Kieback A, Beschorner U and Zeller T. Drug-Coated Balloon Versus Standard Balloon for Superficial Femoral Artery In-Stent Restenosis: The Randomized Femoral Artery In-Stent Restenosis (FAIR) Trial. *Circulation.* 2015;132:2230-6.
32. **Blessing E**. [Update peripheral arterial occlusive disease]. *Herz.* 2015;40:1013-22; quiz 1023-4.
33. Sievers P, Uhlmann L, Korkmaz-Icöz S, Fastner C, Bea F, **Blessing E**, Katus HA and Preusch MR. Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis. *Drug Des Devel Ther.* 2015;9:3935-42.
34. Rastan A, Krankenberg H, Baumgartner I, **Blessing E**, Müller-Hülsbeck S, Pilger E, Scheinert D, Lammer J, Beschorner U, Noory E, Neumann FJ and Zeller T. Stent placement vs. balloon angioplasty for popliteal artery treatment: two-year results of a prospective, multicenter, randomized trial. *J Endovasc Ther.* 2015;22:22-7.
35. Scholz EP, Raake P, Thomas D, Vogel B, Katus HA and **Blessing E**. Rescue renal sympathetic denervation in a patient with ventricular electrical storm refractory to endo- and epicardial catheter ablation. *Clin Res Cardiol.* 2015;104:79-84.
36. Schmidt A, Keirse K, **Blessing E**, Langhoff R and Diaz-Cardelle J. Offroad re-entry catheter system for subintimal recanalization of chronic total occlusions in femoropopliteal arteries: primary safety and effectiveness results of the re-route trial. *J Cardiovasc Surg (Torino).* 2014;55:551-8.
37. Kloos W, Vogel B and **Blessing E**. MiRNAs in peripheral artery disease - something gripping this way comes. *Vasa.* 2014;43:163-70.
38. Kucher N, Boekstegers P, Müller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T, Tebbe U, Horstkotte J, Müller R, **Blessing E**, Greif M, Lange P, Hoffmann RT, Werth S, Barmeyer A, Härtel D, Grünwald H, Empen K and Baumgartner I. Randomized, controlled trial of ultrasound-

assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. *Circulation*. 2014;129:479-86.

39. Vogel B, Kirchberger M, Zeier M, Stoll F, Meder B, Saure D, Andrassy M, Mueller OJ, Hardt S, Schwenger V, Strothmeyer A, Katus HA and **Blessing E**. Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. *Clin Res Cardiol*. 2014;103:117-24.

40. Preusch MR, Baeuerle M, Albrecht C, **Blessing E**, Bischof M, Katus HA and Bea F. GDF-15 protects from macrophage accumulation in a mousemodel of advanced atherosclerosis. *Eur J Med Res*. 2013;18:19.

41. Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, Weil J, Schmidt M, Hoppe UC, Zeller T, Bauer A, Ott C, **Blessing E**, Sobotka PA, Krum H, Schlaich M, Esler M and Böhm M. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. *Circulation*. 2013;128:132-40.

42. Bertog SC, **Blessing E**, Vaskelyte L, Hofmann I, Id D and Sievert H. Renal denervation: tips and tricks to perform a technically successful procedure. *EuroIntervention*. 2013;9 Suppl R:R83-8.

43. Rastan A, Krankenberg H, Baumgartner I, **Blessing E**, Müller-Hülsbeck S, Pilger E, Scheinert D, Lammer J, Gißler M, Noory E, Neumann FJ and Zeller T. Stent placement versus balloon angioplasty for the treatment of obstructive lesions of the popliteal artery: a prospective, multicenter, randomized trial. *Circulation*. 2013;127:2535-41.

44. **Blessing E**, Esler MD, Francis DP and Schmieder RE. Cardiac ablation and renal denervation systems have distinct purposes and different technical requirements. *JACC Cardiovasc Interv*. 2013;6:314.

45. Vogel B, Strothmeyer A, Cebola R, Katus H and **Blessing E**. Crush implantation of a self-expanding interwoven stent over a subintimally recanalized standard stent in a TASC D lesion of the superficial femoral artery. *Vasa*. 2012;41:458-62.

46. Zhou Q, Bea F, Preusch M, Wang H, Isermann B, Shahzad K, Katus HA and **Blessing E**. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. *Mediators Inflamm*. 2011;2011:432080.

47. Morris-Rosenfeld S, **Blessing E**, Preusch MR, Albrecht C, Bierhaus A, Andrassy M, Nawroth PP, Rosenfeld ME, Katus HA and Bea F. Deletion of bone marrow-derived receptor for advanced glycation end products inhibits atherosclerotic plaque progression. *Eur J Clin Invest*. 2011;41:1164-71.

48. Holzhäuser E, Albrecht C, Zhou Q, Buttler A, Preusch MR, **Blessing E**, Katus HA and Bea F. Nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities. *J Cardiovasc Pharmacol*. 2011;57:447-54.

49. Preusch MR, Vanakaris A, Bea F, Ieronimakis N, Shimizu T, Konstandin M, Morris-Rosenfeld S, Albrecht C, Kranzhöfer A, Katus HA, **Blessing E** and Kranzhöfer R. Rosuvastatin reduces neointima formation in a rat model of balloon injury. *Eur J Med Res*. 2010;15:461-7.

50. Remppis A, Bea F, Greten HJ, Buttler A, Wang H, Zhou Q, Preusch MR, Enk R, Ehehalt R, Katus H and **Blessing E**. Rhizoma Coptidis inhibits LPS-induced MCP-1/CCL2 production in murine macrophages via an AP-1 and NFkappaB-dependent pathway. *Mediators Inflamm*. 2010;2010:194896.

51. Zankl AR, Andrassy M, Volz C, Ivandic B, Krumsdorf U, Katus HA and **Blessing E**. Radial artery thrombosis following transradial coronary angiography: incidence and rationale for

- treatment of symptomatic patients with low-molecular-weight heparins. *Clin Res Cardiol*. 2010;99:841-7.
52. Zankl AR, Ivandic B, Andrassy M, Volz HC, Krumsdorf U, **Blessing E**, Katus HA and Tiefenbacher CP. Telmisartan improves absolute walking distance and endothelial function in patients with peripheral artery disease. *Clin Res Cardiol*. 2010;99:787-94.
53. Campbell LA, Yaraei K, Van Lenten B, Chait A, **Blessing E**, Kuo CC, Nosaka T, Ricks J and Rosenfeld ME. The acute phase reactant response to respiratory infection with *Chlamydia pneumoniae*: implications for the pathogenesis of atherosclerosis. *Microbes Infect*. 2010;12:598-606.
54. Zankl AR, **Blessing E**, Volz HC, Krumsdorf U, Katus HA and Andrassy M. Neurological symptoms in acute Leriche's syndrome. *Clin Res Cardiol*. 2010;99:459-62.
55. Albrecht C, Preusch MR, Hofmann G, Morris-Rosenfeld S, **Blessing E**, Rosenfeld ME, Katus HA and Bea F. Egr-1 deficiency in bone marrow-derived cells reduces atherosclerotic lesion formation in a hyperlipidaemic mouse model. *Cardiovasc Res*. 2010;86:321-9.
56. Seehaus S, Shahzad K, Kashif M, Vinnikov IA, Schiller M, Wang H, Madhusudhan T, Eckstein V, Bierhaus A, Bea F, **Blessing E**, Weiler H, Frommhold D, Nawroth PP and Isermann B. Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability. *Circulation*. 2009;120:774-84.
57. Bea F, Hudson FN, Neff-Laford H, White CC, Kavanagh TJ, Kreuzer J, Preusch MR, **Blessing E**, Katus HA and Rosenfeld ME. Homocysteine stimulates antioxidant response element-mediated expression of glutamate-cysteine ligase in mouse macrophages. *Atherosclerosis*. 2009;203:105-11.
58. **Blessing E**. [Coronary heart disease and dyslipidemia - dosing recommendations at beginning and end of treatment]. *Ther Umsch*. 2008;65:593-7.
59. Preusch MR, Rattazzi M, Albrecht C, Merle U, Tuckermann J, Schütz G, **Blessing E**, Zoppellaro G, Pauletto P, Krempien R, Rosenfeld ME, Katus HA and Bea F. Critical role of macrophages in glucocorticoid driven vascular calcification in a mouse-model of atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2008;28:2158-64.
60. Celik S, Doesch A, Erbel C, **Blessing E**, Ammon K, Koch A, Katus HA and Dengler TJ. Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients. *Transplantation*. 2008;86:245-50.
61. Konstandin MH, **Blessing E**, Doesch A, Ammon K, Koch A, Wabnitz GH, Gleissner CA, Remppis A, Katus HA and Dengler TJ. Ezetimibe effectively lowers LDL-cholesterol in cardiac allograft recipients on stable statin therapy. *Clin Transplant*. 2008;22:639-44.
62. **Blessing E**, Preusch M, Kranzhöfer R, Kinscherf R, Marx N, Rosenfeld ME, Isermann B, Weber CM, Kreuzer J, Gräfe J, Katus HA and Bea F. Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. *Atherosclerosis*. 2008;199:295-303.
63. Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, Corat MA, Zeier M, **Blessing E**, Oh J, Gerlitz B, Berg DT, Grinnell BW, Chavakis T, Esmon CT, Weiler H, Bierhaus A and Nawroth PP. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. *Nat Med*. 2007;13:1349-58.
64. Klingenberg R, Nofer JR, Rudling M, Bea F, **Blessing E**, Preusch M, Grone HJ, Katus HA, Hansson GK and Dengler TJ. Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice. *Arterioscler Thromb Vasc Biol*. 2007;27:2392-9.

65. Preusch MR, Bea F, Yang SH, Kreuzer J, Isermann B, Pedal I, Rosenfeld ME, Katus HA and **Blessing E**. Long-term administration of 3-deazaadenosine does not alter progression of advanced atherosclerotic lesions in apolipoprotein E-deficient mice. *J Cardiovasc Pharmacol*. 2007;50:206-12.
66. Marx N and **Blessing E**. [Diabetes mellitus and coronary artery disease. Update on diagnosis and drug therapy]. *Dtsch Med Wochenschr*. 2007;132:1034-8.
67. **Blessing E**, Steen H, Rosenberg M, Katus H and Frey N. Recurrence of takotsubo cardiomyopathy with variant forms of left ventricular dysfunction. *J Am Soc Echocardiogr*. 2007;20:439.e11-2.
68. Bea F, Kreuzer J, Preusch M, Schaab S, Isermann B, Rosenfeld ME, Katus H and **Blessing E**. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. *Arterioscler Thromb Vasc Biol*. 2006;26:2787-92.
69. Kamimura M, Viedt C, Dalpke A, Rosenfeld ME, Mackman N, Cohen DM, **Blessing E**, Preusch M, Weber CM, Kreuzer J, Katus HA and Bea F. Interleukin-10 suppresses tissue factor expression in lipopolysaccharide-stimulated macrophages via inhibition of Egr-1 and a serum response element/MEK-ERK1/2 pathway. *Circ Res*. 2005;97:305-13.
70. **Blessing E**, Rottbauer W, Mereles D, Hosch W, Benz A, Friess H, Autschbach F, Müller M, Stremmel W and Katus H. Isolated left ventricular noncompaction of the myocardium as a cause of embolic superior mesenteric artery occlusion. *J Am Soc Echocardiogr*. 2005;18:693.
71. **Blessing E**, Campbell LA, Rosenfeld ME, Chesebro B and Kuo CC. A 6 week course of azithromycin treatment has no beneficial effect on atherosclerotic lesion development in apolipoprotein E-deficient mice chronically infected with *Chlamydia pneumoniae*. *J Antimicrob Chemother*. 2005;55:1037-40.
72. **Blessing E**, Bea F, Kuo CC, Campbell LA, Chesebro B and Rosenfeld ME. Lesion progression and plaque composition are not altered in older apoE^{-/-} mice lacking tumor necrosis factor- α receptor p55. *Atherosclerosis*. 2004;176:227-32.
73. Bea F, **Blessing E**, Bennett BJ, Kuo CC, Campbell LA, Kreuzer J and Rosenfeld ME. Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. *Cardiovasc Res*. 2003;60:198-204.
74. Chesebro BB, **Blessing E**, Kuo CC, Rosenfeld ME, Puolakkainen M and Campbell LA. Nitric oxide synthase plays a role in *Chlamydia pneumoniae*-induced atherosclerosis. *Cardiovasc Res*. 2003;60:170-4.
75. Bea F, **Blessing E**, Shelley MI, Shultz JM and Rosenfeld ME. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. *Atherosclerosis*. 2003;167:187-94.
76. Bea F, **Blessing E**, Bennett B, Levitz M, Wallace EP and Rosenfeld ME. Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. *Arterioscler Thromb Vasc Biol*. 2002;22:1832-7.
77. Seeger FH, **Blessing E**, Gu L, Bornhold R, Denger S and Kreuzer J. Fibrinogen induces chemotactic activity in endothelial cells. *Acta Physiol Scand*. 2002;176:109-15.
78. **Blessing E**, Campbell LA, Rosenfeld ME and Kuo CC. *Chlamydia pneumoniae* and hyperlipidemia are co-risk factors for atherosclerosis: infection prior to induction of hyperlipidemia does not accelerate development of atherosclerotic lesions in C57BL/6J mice. *Infect Immun*. 2002;70:5332-4.
79. **Blessing E**, Kuo CC, Lin TM, Campbell LA, Bea F, Chesebro B and Rosenfeld ME. Foam cell formation inhibits growth of *Chlamydia pneumoniae* but does not attenuate *Chlamydia pneumoniae*-induced secretion of proinflammatory cytokines. *Circulation*. 2002;105:1976-82.

80. **Blessing E**, Campbell LA, Rosenfeld ME, Chough N and Kuo CC. Chlamydia pneumoniae infection accelerates hyperlipidemia induced atherosclerotic lesion development in C57BL/6J mice. *Atherosclerosis*. 2001;158:13-7.
81. Bär H, Bea F, **Blessing E**, Watson L, Wende P, Kreuzer J, Kübler W and Jahn L. Phosphorylation of cytokeratin 8 and 18 in human vascular smooth muscle cells of atherosclerotic lesions and umbilical cord vessels. *Basic Res Cardiol*. 2001;96:50-8.
82. **Blessing E**, Nagano S, Campbell LA, Rosenfeld ME and Kuo CC. Effect of Chlamydia trachomatis infection on atherosclerosis in apolipoprotein E-deficient mice. *Infect Immun*. 2000;68:7195-7.
83. **Blessing E**, Lin TM, Campbell LA, Rosenfeld ME, Lloyd D and Kuo C. Chlamydia pneumoniae induces inflammatory changes in the heart and aorta of normocholesterolemic C57BL/6J mice. *Infect Immun*. 2000;68:4765-8.
84. Fong IW, Quinn T, **Blessing E**, Kuo C, Malinverni R, Lauer M, Mawhorter S, Bachmaier K, Rosenfeld M, Taylor C and Zhong G. Collaborative multidisciplinary workshop report: what questions regarding the role of Chlamydia pneumoniae in atherosclerosis and cardiovascular disease need to be addressed utilizing animal models? *J Infect Dis*. 2000;181 Suppl 3:S519-20.
85. Campbell LA, **Blessing E**, Rosenfeld M, Lin T and Kuo C. Mouse models of C. pneumoniae infection and atherosclerosis. *J Infect Dis*. 2000;181 Suppl 3:S508-13.
86. Rosenfeld ME, **Blessing E**, Lin TM, Moazed TC, Campbell LA and Kuo C. Chlamydia, inflammation, and atherogenesis. *J Infect Dis*. 2000;181 Suppl 3:S492-7.
87. Bea F, Bär H, Watson L, **Blessing E**, Kübler W, Kreuzer J and Jahn L. Cardiac alpha-actin in smooth muscle cells: detection in umbilical cord vessels and in atherosclerotic lesions. *Basic Res Cardiol*. 2000;95:106-13.
88. **Blessing E**, Hausmann D, Sturm M, Wolpers HG, Amende I and Mügge A. Incomplete expansion of Palmaz-Schatz stents despite high-pressure implantation technique: impact on target lesion revascularization. *Cardiology*. 1999;91:102-8.
89. **Blessing E**, Hausmann D, Sturm M, Wolpers HG, Amende I and Mügge A. Intravascular ultrasound and stent implantation: intraobserver and interobserver variability. *Am Heart J*. 1999;137:368-71.
90. Sturm M, Hausmann D, Mügge A, **Blessing E** and Amende I. Dislodgement of a Wiktor stent during intracoronary ultrasound examination. *Cardiology*. 1997;88:530-2.
91. Oberhoff M, Baumbach A, Herdeg C, Hassenstein S, Xie DY, **Blessing E**, Hanke H, Haase KK, Betz E and Karsch KR. Smooth excimer laser coronary angioplasty (SELCA) and conventional excimer laser angioplasty: Comparison of vascular injury and smooth muscle cell proliferation. *Lasers Med Sci*. 1997;12:328-35.
92. Hausmann D, **Blessing E**, Mügge A, Sturm M, Wolpers HG, Rafflenbeul W and Amende I. Angiographically undetected plaque in the left main coronary artery. Findings of intravascular ultrasound imaging. *Int J Card Imaging*. 1997;13:293-9.
93. Baumbach A, Oberhoff M, Bohnet A, Miljak T, Herdeg C, Horch B, **Blessing E**, Kunert W, Haase KK and Karsch KR. Efficacy of low-molecular-weight heparin delivery with the Dispatch catheter following balloon angioplasty in the rabbit iliac artery. *Cathet Cardiovasc Diagn*. 1997;41:303-7.
94. **Blessing E**, Wolpers HG, Hausmann D, Mügge A and Amende I. Posttraumatic myocardial infarction with severe coronary intimal dissection documented by intravascular ultrasound. *J Am Soc Echocardiogr*. 1996;9:906-8.
95. Riessen R, Isner JM, **Blessing E**, Loushin C, Nikol S and Wight TN. Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. *Am J Pathol*. 1994;144:962-74.

96. Riessen R, Rahimizadeh H, **Blessing E**, Takeshita S, Barry JJ and Isner JM. Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon. *Hum Gene Ther.* 1993;4:749-58.